Retatrutide: mechanism of action

Retatrutide, also known by the development code LY3437943, is an investigational triple receptor agonist acting at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors [1][3]. It is being studied for chronic weight management and for type 2 diabetes mellitus, and it has no established role in type 1 diabetes mellitus [1][3]. The evidence block supplied for this page does not include a sequence, molecular formula or molecular weight for the molecule, so none is stated here. The compound is supplied to laboratories as a research peptide; the catalogue entry for the research-grade material is Retatrutide.

The work on this compound centres on the incretin and glucagon receptor families — specifically the simultaneous engagement of GIPR, GLP-1R and GCGR, a combination that distinguishes it from single- and dual-agonist comparators in the same therapeutic area [1][2][3].

Research Studies

Retatrutide and receptor pharmacology in investigational drug development

Retatrutide is described in the clinical literature as a novel triple agonist of the GIP, GLP-1 and glucagon receptors, under investigation for obesity and type 2 diabetes mellitus [1]. The same source notes that it has no established role in type 1 diabetes mellitus, which is relevant when interpreting reports of its use outside supervised research settings [1]. A separate registry record describes the same molecule, LY3437943, as an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management [3].

Retatrutide and renal fibrosis in UUO and aged mouse models

In a comparative study of semaglutide, tirzepatide and retatrutide, anti-fibrotic and anti-inflammatory effects were evaluated in non-diabetic renal fibrosis using HK-2 cells together with murine unilateral ureteral obstruction (UUO) and aging models [2]. Integrating in vivo and in vitro data, the authors reported model- and drug-specific patterns of action among the three agents [2]. In the UUO model, retatrutide effects were associated with concurrent inhibition of both PI3K-AKT and NF-κB pathways, whereas semaglutide effects were associated with PI3K-AKT inhibition and tirzepatide effects with PI3K-AKT inhibition plus PPAR pathway activation [2].

Retatrutide and metabolic endpoints in diet-induced obese MASH mouse and hamster models

In diet-induced obese MASH mouse and hamster models, retatrutide was evaluated as a triple glucagon, GIP and GLP-1 receptor agonist [4]. In mice, retatrutide reduced body weight by 31% (p < 0.0001 versus vehicle), reducing both fat and lean mass, and reduced food and water intake during the first days of treatment, while energy expenditure was not altered significantly [4]. The same study reported marked reductions in the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides and total cholesterol content in mice, with alterations also observed in hamsters [4]. These are animal-model findings and are reported here as such.

Retatrutide and glycaemic response in type 2 diabetes mellitus clamp studies

A registered study is designed to measure the effect of once-weekly retatrutide versus placebo on time to recovery from hypoglycemia during a hypoglycemic clamp in participants with type 2 diabetes mellitus following 16 weeks of treatment [7]. A separate registered study has as its primary objective the comparison of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment in adult participants with type 2 diabetes mellitus, evaluating effects on insulin secretion and insulin sensitivity [8]. Both are interventional protocols; the evidence block reports their objectives rather than results.

Retatrutide and body weight reduction in adults with obesity or overweight

A registered study is designed to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction, with participation lasting about 65 weeks and possibly including about 18 visits [6]. A further registered study investigates the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight, with participation lasting about 113 weeks [5].

Retatrutide and pre-approval expanded access in severe obesity

A pre-approval single-patient expanded access record describes provision of retatrutide (LY3437943) for adults with severe obesity, defined as a body mass index greater than or equal to 35 kg/m² with at least two serious or life-threatening obesity-related complications, who are refractory to the best approved therapy and unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine [3]. This is an access mechanism, not an efficacy study, and the evidence block reports no outcomes from it.

Retatrutide and cardiovascular risk biomarkers in adults with obesity, with or without type 2 diabetes

In a post hoc analysis of phase 2 trials, lipoprotein and inflammatory biomarkers were assessed in adults with obesity or overweight, with or without type 2 diabetes, to further characterise effects on cardiometabolic risk [10]. The analysis drew on data from two randomised, double-blind trials [10]. This source is reference material supporting the page rather than a study described in detail here.

Retatrutide and product composition in the unregulated supply chain

A study examined the composition and labelling accuracy of products sold as retatrutide in Australia [9]. Separately, a case report describes a man in his mid-30s with longstanding type 1 diabetes mellitus who developed complicating impending diabetic ketoacidosis in the context of online-sourced retatrutide use and concurrent Shigella gastroenteritis [1]. That report notes that growing public interest in incretin-based therapies has been accompanied by increasing availability of research peptides purchasable online, that such products may be used without medical assessment or counselling regarding adverse effects, sick-day management or follow-up, and that composition, purity and dosing accuracy may be uncertain [1]. These observations concern the supply and use context of research peptides, not the intrinsic pharmacology of the molecule.

Retatrutide and cognition in diabetic rat models

Preclinical work has examined retatrutide effects on cognition in diabetic rats [12]. This source is reference material supporting the page; the evidence block does not supply the endpoints or outcomes, so no findings are stated here.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research use only, and we do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing here is a recommendation, a protocol, or a substitute for professional medical advice.

Sources

• [1] Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis — https://europepmc.org/article/PMC/PMC13525912
• [2] Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice — https://europepmc.org/article/PMC/PMC13495082
• [3] Pre-approval Expanded Access of Retatrutide (LY3437943) — https://clinicaltrials.gov/study/NCT07629401
• [4] Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models — https://europepmc.org/article/PMC/PMC13250738
• [5] A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight — https://clinicaltrials.gov/study/NCT07357415
• [6] A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight — https://clinicaltrials.gov/study/NCT07232719
• [7] A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia — https://clinicaltrials.gov/study/NCT06982846
• [8] A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus — https://clinicaltrials.gov/study/NCT06982859
• [9] Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia — https://europepmc.org/article/PMC/PMC13445994
• [10] Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/42608321/
• [11] Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it — https://pubmed.ncbi.nlm.nih.gov/42567543/
• [12] Retatrutide effects on diabetic rats' cognition — https://pubmed.ncbi.nlm.nih.gov/42527705/